The results are EPIC1,2
Groundbreaking results of the EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study, the largest veterinary cardiology study in history, are now published.
in time to composite primary endpoint compared with dogs receiving placebo*
in asymptomatic Stage B2
of heart disease*
10% more life
without CHF signs that impact quality of life or
PROVEN BENEFITS OF EARLY TREATMENT OF MYXOMATOUS MITRAL VALVE DISEASE (MMVD)—BEFORE CONGESTIVE HEART FAILURE (CHF)1
The EPIC Study showed a significant benefit in administering pimobendan in dogs with preclinical MMVD—before the onset of CHF, cardiac-related death, or euthanasia (composite primary endpoint).VIEW FINDINGS
WHAT DOES THE EPIC STUDY MEAN FOR VETERINARIANS?
Discover how veterinarians can apply the findings of the EPIC Study to their clinical practice.LEARN WHY THE EPIC STUDY IS SO IMPORTANT
HEAR FROM THE INVESTIGATORS
The EPIC Study represents a significant advancement in canine cardiology.
Watch the lead investigators discuss the implications of this groundbreaking study.
WHAT DOES THE EPIC STUDY MEAN FOR DOGS AND THEIR OWNERS?
For pet owners, the EPIC Study results demonstrate how early treatment of MMVD can help dogs live longer, free from the symptoms of CHF.LEARN MORE
DIAGNOSING AND MANAGING PRECLINICAL MMVD
EPIC Study results can empower veterinarians to identify MMVD early and achieve better outcomes for their patients.LEARN MORE
DETAILS ABOUT THE EPIC STUDY
First published in 2016, the EPIC Study is the largest prospective,
randomised clinical study in veterinary cardiology history1
2nd EPIC Study publication findings
Use of pimobendan significantly reduced heart size in dogs
with Stage B2 myxomatous mitral valve disease (MMVD)1,2
Findings from the 3rd EPIC Study publication
In dogs with Stage B2 myxomatous mitral valve disease (MMVD), routine and frequent measuring of clinic respiratory rate and home resting respiratory rate may result
in earlier detection of congestive heart failure3